Jörn M Schattenberg1. 1. Metabolic Liver Research Program, First Department of Medicine, University Medical Center Mainz, Mainz, Germany.
Abstract
BACKGROUND: The increasing prevalence of nonalcoholic -fatty liver disease has led to a strong demand for an optimal therapeutic approach. At present, guidelines recommend lifestyle changes, but it has become apparent that pharmacotherapy will be required in patients with advanced disease to prevent the progression to end-stage liver disease and potentially improve extrahepatic outcomes. SUMMARY: This review discusses current pharmacological approaches focusing on substances studied in pivotal trials and selected phase 2 trials in patients with nonalcoholic steatohepatitis (NASH) and fibrosis. KEY MESSAGE: Currently, several compounds are subjected to clinical testing to explore predominantly anti-inflammatory, anti-fibrotic, and metabolic treatment for NASH. With current response rates around 20%, the combination of several drugs targeting more than one pathway could lead to increased treatment success in the future.
BACKGROUND: The increasing prevalence of nonalcoholic -fatty liver disease has led to a strong demand for an optimal therapeutic approach. At present, guidelines recommend lifestyle changes, but it has become apparent that pharmacotherapy will be required in patients with advanced disease to prevent the progression to end-stage liver disease and potentially improve extrahepatic outcomes. SUMMARY: This review discusses current pharmacological approaches focusing on substances studied in pivotal trials and selected phase 2 trials in patients with nonalcoholic steatohepatitis (NASH) and fibrosis. KEY MESSAGE: Currently, several compounds are subjected to clinical testing to explore predominantly anti-inflammatory, anti-fibrotic, and metabolic treatment for NASH. With current response rates around 20%, the combination of several drugs targeting more than one pathway could lead to increased treatment success in the future.
Authors: Stephen A Harrison; Mary E Rinella; Manal F Abdelmalek; James F Trotter; Angelo H Paredes; Hays L Arnold; Marcelo Kugelmas; Mustafa R Bashir; Mark J Jaros; Lei Ling; Stephen J Rossi; Alex M DePaoli; Rohit Loomba Journal: Lancet Date: 2018-03-05 Impact factor: 79.321
Authors: Zobair M Younossi; Vlad Ratziu; Rohit Loomba; Mary Rinella; Quentin M Anstee; Zachary Goodman; Pierre Bedossa; Andreas Geier; Susanne Beckebaum; Philip N Newsome; David Sheridan; Muhammad Y Sheikh; James Trotter; Whitfield Knapple; Eric Lawitz; Manal F Abdelmalek; Kris V Kowdley; Aldo J Montano-Loza; Jerome Boursier; Philippe Mathurin; Elisabetta Bugianesi; Giuseppe Mazzella; Antonio Olveira; Helena Cortez-Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean-Francois Dufour; David Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen Harrison; Arun J Sanyal Journal: Lancet Date: 2019-12-05 Impact factor: 79.321
Authors: Vlad Ratziu; Stephen A Harrison; Sven Francque; Pierre Bedossa; Philippe Lehert; Lawrence Serfaty; Manuel Romero-Gomez; Jérôme Boursier; Manal Abdelmalek; Steve Caldwell; Joost Drenth; Quentin M Anstee; Dean Hum; Remy Hanf; Alice Roudot; Sophie Megnien; Bart Staels; Arun Sanyal Journal: Gastroenterology Date: 2016-02-11 Impact factor: 22.682
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Naiara Beraza; Lisa Ofner-Ziegenfuss; Haksier Ehedego; Mark Boekschoten; Stephan C Bischoff; Michael Mueller; Michael Trauner; Christian Trautwein Journal: Gut Date: 2010-11-29 Impact factor: 31.793